abametapir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5403 1762-34-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • abametapir
  • xeglyze
  • Ha44
Abametapir is a metalloproteinase inhibitor. Metalloproteinases have a role in physiological processes critical to egg development and survival of lice.
  • Molecular weight: 184.24
  • Formula: C12H12N2
  • CLOGP: 2.56
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 25.78
  • ALOGS: -2.27
  • ROTB: 1

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
July 24, 2020 FDA DR REDDYS LABS SA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC P03AX07 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS
ECTOPARASITICIDES, INCL. SCABICIDES
Other ectoparasiticides, incl. scabicides

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pediculosis capitis indication 81000006 DOID:5501




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.74% XEGLYZE HATCHTECH N206966 July 24, 2020 DISCN LOTION TOPICAL 8212038 July 16, 2024 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
0.74% XEGLYZE HATCHTECH N206966 July 24, 2020 DISCN LOTION TOPICAL 9839631 July 16, 2024 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
0.74% XEGLYZE HATCHTECH N206966 July 24, 2020 DISCN LOTION TOPICAL 7812163 Oct. 28, 2026 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
0.74% XEGLYZE HATCHTECH N206966 July 24, 2020 DISCN LOTION TOPICAL 10292389 Dec. 17, 2034 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.74% XEGLYZE HATCHTECH N206966 July 24, 2020 DISCN LOTION TOPICAL July 24, 2025 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
C-C chemokine receptor type 5 GPCR EC50 5.64 CHEMBL
C-C chemokine receptor type 1 GPCR EC50 4.80 CHEMBL
C-C chemokine receptor type 8 GPCR EC50 5.12 CHEMBL

External reference:

IDSource
D10687 KEGG_DRUG
6UO390AMFB UNII
C4519258 UMLSCUI
EI3 PDB_CHEM_ID
CHEMBL2205807 ChEMBL_ID
15664 PUBCHEM_CID
DB11932 DRUGBANK_ID
018457 NDDF
926368006 SNOMEDCT_US
926389002 SNOMEDCT_US
2475532 RXNORM
38681 MMSL
9829 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xeglyze HUMAN PRESCRIPTION DRUG LABEL 1 43598-921 LOTION 0.74 g TOPICAL NDA 25 sections